Cite
Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
MLA
Palumbo, A. P., et al. “Consolidation Treatment with Dexamethasone and Alpha-2B Recombinant Interferon Further Reduces the M-Component Level in Multiple Myeloma Patients Responding to Conventional Induction Chemotherapy.” Haematologica, vol. 75, no. 6, Nov. 1990, pp. 576–78. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=2098302&authtype=sso&custid=ns315887.
APA
Palumbo, A. P., Garino, A. L., Frieri, R., Gallone, G., Boccadoro, M., & Pileri, A. (1990). Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy. Haematologica, 75(6), 576–578.
Chicago
Palumbo, A P, A L Garino, R Frieri, G Gallone, M Boccadoro, and A Pileri. 1990. “Consolidation Treatment with Dexamethasone and Alpha-2B Recombinant Interferon Further Reduces the M-Component Level in Multiple Myeloma Patients Responding to Conventional Induction Chemotherapy.” Haematologica 75 (6): 576–78. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=2098302&authtype=sso&custid=ns315887.